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INTRODUCTION
Scientific debate on hepatitis at the beginning of the 20th 
century focused mainly on the aetiology of the “icterus 
catharralis”1. After the 2nd World War discussion centered 
on a probable infectious agent. Since the 1960s, after the 
identification by Baruch Blumberg of the Australia anti-
gen2, other agents of viral hepatitis (VH) have been identi-
fied. Transaminases and hepatic biopsy in the 1950s, and 
serological diagnosis, gave additional visibility to the VH 
and contributed to the growing efforts on research of pas-
sive and active immunization of the 1970/1980s. From 1990 
on, the hepatitis C pandemic helped to focus scientific and 
economic interests in the production of drugs. Research 
methods and goals changed but phase three experiments – 
clinical trials – still require interventions in people. 
The history of diseases provides many examples of re-
search in human beings, volunteers or not. In the case of 
hepatitis, resistance of the scientific community to accept 
its infective etiology1, in part due to the difficulty of devel-
oping an experimental animal model3, may have stimulat-
ed even more experiments in human populations. While 
the aetiology of hepatitis was being discussed, leptospiro-
sis and yellow fever – diseases whose predominant clini-
cal presentation (icterus and fever) include them in the 
same key for differential diagnosis – already had clearly 
defined aetiology, animal models for research, and diag-
nostic tests4. Although recognized as “campaign jaundice”5 
since 1915, it was only during World War II, when 200.000 
American soldiers and five million German militaries and 
civilians were struck by it, that emerged “a great impetus to 
the understanding and prevention of the disease”6. 
In the 1960s, human blood, feces, and secretions from 
the sick were  inoculated in volunteers to try to understand 
transmission and propose prevention of the hepatitis. 
Nowadays, experiments in anima nobile require compli-
ance to ethical requirements and the informed consent is 
sine qua non to their implement7.
We discuss contradictory aspects of the informed con-
sent in classical human experiments on hepatitis in the 
first half of the 20th century in view of the design of clinical 
trials today.
We bring to discussion particular aspects of the experi-
ments in anima nobile on hepatitis through a selection of 
classic studies pointing to contradictory ethical aspects in-
cluding the informed consent. Many authors have shown 
the advances in legislation on ethical issues concerning re-
search in human subjects8,9. Research on AIDS has been, 
on the last two decades, at the center of debates that em-
phasize the concepts of vulnerability and difference or di-
versity as attributes of social groups and individuals, that 
should be of special concern as ethical issues of research 
protocols10. Studies on hepatitis seem to point to similar is-
sues although they were not frequently the object of debate 
in the old days. These questions are discussed considering 
sociocultural and time diversities, focusing the multiple 
dimensions that derive from technology and scientific 
uncertainties.
THE INFORMED CONSENT
Although the informed consent, included in the CNS 
Resolution 196/1996 as free and informed consent, is rela-
tively new7, recognition of its relevance was presented at 
the turn of the 20th century11. The Parliament of Prussia in 
1898 asked for government action, motivated by contro-
versies concerning the research on syphilis prevention that 
required inoculation of serum from patients in prostitutes, 
who became ill. The Rudolf Virchow’s report concluded 
that no physician was allowed to inject infective serum in 
a volunteer without previous consent11.
Krugman and Giles12, authors of the studies on hepati-
tis at Willowbrook State School (WSS) between 1956 and 
1970, begin their research at the same year of the elabora-
tion of the Project for the Code on Ethics in Experiments 
on Human Subjects that was presented at the General As-
sembly of the World Medical Association in 1961. The au-
thors refer that the studies at WSS were in accordance with 
the Project that allowed research with legally incompetent 
subjects once the informed consent of their legal represen-
tatives was obtained12,13. In 1964 this Project was revised 
into what became known as the Declaration of Helsinki 
and presented a more restrictive version concerning the 
legally incapable although maintaining the possibility of 
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their participation as subjects of research14. Similarly, the 
Brazilian CNS Resolution 196/96 (item IV.3)7 also admits 
research involving children and adolescents with restricted 
mental capabilities or mental disease and subjects with im-
paired capabilities to provide consent, requiring that the 
protocol provide clear justification for this choice of re-
search subjects and that informed consent is provided by 
legal representatives, and information is provided to the 
subjects to the limits of their capabilities. 
Vollmann and Winau11 point out that even before the 
Nuremberg Code in 194715 – that established that only 
the legally capable should be able to volunteer as subjects 
of research experiments – regulations derived from public 
debate and from the Prussian Parliament in the 1900 were 
more restrictive and provided that “minors and incompe-
tent subjects were generally excluded from non-therapeutic 
research, as they could not give valid informed consent.” 
Nevertheless, as pointed out by Kotow16, it was the Bel-
mont Report in 1978 that developed in its full complexity the 
principles of autonomy, beneficence, non-maleficence, jus-
tice and equity regarding the research in human subjects17. 
This report came to light six years after the closing of the 
hepatitis research unit at WSS in 197218. Publication of 
the results of the WSS studies provided the ground for a 
broad debate on ethics in research6,18-20, and some of the ar-
guments for and against these protocols seem to have been 
recently rekindled in the debate on ethics in AIDS research 
protocols in Africa. Garrafa and Prado10 show the relevance 
of revisiting the past as they expose the many social and 
economic issues that may be involved in proposals of ethi-
cal relativity.  
THE ARGUMENT OF HIGH ENDEMICITY
Nowadays, electing volunteers for research requires a meth-
odology that guarantees the control of selection biases and 
of ethical principles. The choice of sex professionals could 
be justified by the perspective of development of therapies 
and preventive measures for diseases with higher inci-
dence/prevalence in that population. In 1970, Krugman e 
Giles12 justified an experimental study that had lasted 14 
years, with the argument of high endemicity of hepatitis 
in an institution for special children (Willowbrook State 
School). In 2011, the European & Developing Countries 
Clinical Trials Partnership (EDCTP) – non-governmental 
organization founded on 2003 – considering Sub-Saharan 
Africa as the most affected region in the world regarding 
these infections, impairing its development and leading to 
extreme poverty, took as a mission “to accelerate the de-
velopment of new or improved drugs, vaccines and micro-
bicides against HIV/AIDS, malaria and tuberculosis, with 
a focus on phase II and III clinical trials in Sub-Saharan 
Africa”21. HIV, malaria and tuberculosis were selected for 
the discussion of the argument of high endemicity because 
these diseases present nowadays scientific challenges and 
social mobilization for their control that seem similar to 
the situation of hepatitis when the WSS experiments were 
underway. What are the implications of using diverse ethi-
cal criteria in experiments in anima nobile? To study the 
progression of HIV infection can we inject live malaria 
parasites in HIV patients in China, even if this protocol 
has been rejected in the USA? Lurie and Wolfe22 ask these 
questions, and answer that “these are not simply hypotheti-
cal worst-case scenarios”; this research has “already been 
performed”. 
Kotow9, discussing the informed consent on clinical 
trials, presents the question of vulnerability of populations 
of some countries that corroborate such studies suggesting 
that their position as underdeveloped countries may gener-
ate almost colonial relations that may limit their capacity to 
adequately defend the interests of their population. 
Carvalheiro23 points out that the inclusion of developing 
countries in studies of HIV vaccine developments seem to 
be justified not only by the genetic variability of HIV but 
also to elude the vigilance of regulatory agencies, so often 
inexistent or careless of such questions in the Third World. 
What are the differences between the questions raised by 
Carvalheiro23 and the Willowbrook study12? In the first case, 
the autonomy of the subjects can be limited by not so well 
understood research protocols and the unquestionable sci-
entific authority of the principal investigators. In the second 
case, the autonomy of the subjects was transferred to the 
parents or legal guardians that were informed that the chil-
dren could be benefited by immunity against the disease. 
Krugman and Giles12 took extreme care to justify the 
human experiment and the process of obtaining informed 
consent. For instance they argued that since the susceptible 
children would be invariably infected when interned at 
WSS, artificial induction of hepatitis could have a therapeu-
tic effect. They also comment that only the children whose 
parents had given written informed consent were included 
in the study and that the technique to obtain the consent 
had evolved with time. With the strategy of group meet-
ings involving families and a multidisciplinary team (social 
psychiatry specialist, physician, nurse and attendants) they 
obtained more agreements.
However, we should pose a question – to avoid anach-
ronism in the judgment of the procedures of the past24 – as 
to the possible inuence of the list of renowned institutions 
that approved the research protocol on the agreement of 
the parents. How many parents of special children, for so 
long segregated, in the USA or anywhere, in the 1950s (or 
today), would be able to decide freely the consent to a study 
informed to be prophylactic and sanctioned by so many 
well-known scientific institutions? 
To answer this we recall the critics of that time such as 
Goldby20. In his letter to The Lancet, he emphasizes that 
the “duty of a paediatrician in a situation such as exists at 
Willowbrook State School is to attempt to improve that 
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situation, not to turn it to his advantage for experimen-
tal purposes, however lofty the aims.” The Editor seems 
to ratify this opinion commenting on the affirmative that 
the study was therapeutical: “It is hard to accept that view, 
even when applied to a school where a very high propor-
tion of children will, in existing conditions, be infected 
anyway” 20. These comments suggest that the institution 
was not considered as a model and that many parents 
could be leaving their children there for lack of options. It 
shows the possibility of a situation of extreme vulnerability 
of these families of children with special needs back in the 
1950/1960, even in the USA.   
We can imagine similar situations in populations whose 
only possible access to medication may be linked to the 
consent to participate in clinical trials. It seems to have oc-
curred in the AIDS Clinical Trials Group Study 076 (ACTG 
076) when, after years of proven efficacy and widespread 
use of the antiviral zidovudine for prevention of perinatal 
transmission of HIV in the USA, pregnant women in other 
countries still had no access to such medication22.
CLINICAL TRIALS AND PARTIALLY KNOWN RESULTS
Although Saul Krugman passed into history as a pioneer 
of hepatitis B vaccination6, many of the more than 700 
subjects of the Willowbrook Studies were not immu-
nized12. They became chronically infected, as observed 
by the researchers, although they had no means at that 
time to further understand their findings: “The extremely 
long-term, if not permanent, persistence of Au/SH ob-
served in nine of the 18 children in whom it was found 
suggests that it is not a very efficient antigen in terms of 
antibody stimulation or that the antibodies that it induces 
are incomplete”25.
Observing these experiments with todays knowledge, 
it seems hardly justifiable to inject or ask the subjects to 
swallow solutions of feces from icteric patients26. But, in 
1945 it was not possible to predict all the consequences 
of this procedure. Even today, possible adverse effects of 
new drugs are very hard to be fully predicted before they 
are licensed to use and we are familiar with the many in-
stances of the need for drug recall such as pointed out in 
the classical study by Beecher27. The frequency of human 
experiments on hepatitis was criticized in 1952 by Fraga 
Filho28 who considered that the number of human experi-
ments on etiology of hepatitis with similar results no lon-
ger needed further trials. Tables 1 and 2, reproduced from 
his doctoral thesis, show the evidence for his argument. 
Here are registered the number of volunteers, the authors, 
and the period of the study.  
MacCallum29 published a similar review for serum 
hepatitis presenting eight experimental studies in anima 
nobile, that took place from 1944 to 1946, with the innocu-
lation of 548 people, 184 (33,6%) of them presenting icter-
us. The disease followed the reception of measles convales-
cent serum and yellow fever vaccine that contained human 
serum. The author remarks that “[...] as a result of the use 
of blood products on a massive scale during the period 
1939-1945, a sufficient number of different ‘outbreaks’ of 
homologous serum hepatitis occurred [...]” and that, as the 
disease “[...] could not transmitted to laboratory animals 
experimental studies have been carried out in man”. Ap-
parently without perception of any contradiction, he also 
describes methods of inactivation of the icterogenic agent 
and points that it is desirable to have a routine method for 
serum treatment that would inactivate this agent without 
destroying the desirable serum properties. 
The perception of the uncertainty of scientific knowl-
edge makes us aware of the need to constantly question 
and adequate the meanings and uses of the informed con-
sent30. The fragility of the informed consent and the auton-
omy of volunteers and researchers themselves, stand out 
when we reect about scientific research from a historical 
perspective.
KOCH´S POSTULATES AND SCIENTIFIC UNCERTAINTY
In the beginning of the 20th century, biomedical research of 
infectious diseases causality was ruled by the Koch’s postu-
lates and it was in this scenario where most experimental 
studies on hepatitis were developed. 
The hypothesis of an infectious nature of icterus 
catharralis presented difficulties for lack of animal models 
or in vitro data, as required by the postulates, and human 
experiments were done to check the hypothesis. In a 1945 
article, co-written by Albert Sabin, we read: “and by using 
man as the experimental animal some of the properties of 
the agent of infectious hepatitis have been determined”31. 
Not only the difficulties of the animal model but also 
the search for irrefutable evidence stimulated studies on 
human volunteers, often disregarding the unnecessary 
risks the volunteers could be standing3,4.
In 1967, Deinhardt et al. registered that marmosets 
were susceptible to human hepatitis and could be ap-
propriate animal models. But, avoiding criticism, the au-
thors emphasized that although they had demonstrated 
the transmission of human hepatitis to those primates 
through the elevation of transaminases and compatible 
liver lesions they could not confirm it through the eleva-
tion of antibodies. That ratified the need for caution in the 
interpretation of the results and justified further human 
experiments: “It is yet to be proved that the agent induc-
ing hepatitis in marmosets is indeed the agent of human 
viral hepatitis by the reintroduction of the agent after sev-
eral marmoset passages into man”32. 
Koch’s postulates are insufficient for the standards of 
today. As was seen later, the non-reproduction of hepatitis 
in experiments with animals32 was overcome by electron 
microscopes and molecular biology that made possible the 
identification of HAV and HCV. 
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Material Author Year Disease stage
Route of 
administration
Nr. of 
volunteers Positive results
Incubation
(days)
Jaundice
Without 
jaundice
Duodenal 
liquid
Feces
Voegt (467) 1942 Preicteric Oral 4 2 2 28
Mac Callum and  
Bradley (280)
1944
Icteric and 
preicteric
Nasopharynx 26 3 – 27-31
Havens (181) 1944-46 Icteric Oral 12 9 – 15-27
Havens (185) 1946
Incubation  
(-15 days)
Oral 3 – – –
Havens (185) 1946
Convalescence 
(+25 to  
31 days)
Oral 10 – – –
Neefe et al. (334) 1944-46 Icteric Oral 49 28 2 17-32
Neefe et al. (334) 1944-46 Icteric Parenteral 3 – – –
Neefe et al. (335) 1945
21 days 
posticteric
Oral 7 – – –
Neefe et al. (335) 1947
+92 to  
+342 days
Oral 5 – 3 18-20
Findlay and Wilcox (123) 1945 Icteric Oral 73 7 10 17-48
Paul et al. (357) 1945 Icteric Oral 3 2 – 20-25
Serum
Voegt (467) 1942 Preicteric Parenteral 4 – 2 19 (?)
Cameron (46) 1943 Icteric Parenteral 7 6 – 30
Mac Cullum and  
Bradley (280)
1944 Icteric Parenteral 6 3 – 64-92
Havens (181) 1944-46 Icteric Parenteral 17 8 – 20-31
Havens (181) 1944-46 Icteric Oral 8 7 – 21-34
Havens (185) 1946
Convalescence 
(+25 to  
+31 days)
(?) 10 – – –
Oliphant (348) 1944 Icteric Parenteral 21 4 – 85-106
Francis (143) 1946 Preicteric Parenteral 8 4 – 42-47
Oram (353) 1945
Multiple  
stages
Parenteral 9 – – –
Neefe et al. (334) 1944-46 Icteric Parenteral 9 1 1 30
Neefe et al. (334) 1944-46 Icteric Oral 3 2 – 26-33
Neefe et al. (333) 1947
Chronic (106  
to 367 days)
Oral 5 – – –
Paul et al. (357) 1945 Preicteric Parenteral 11 6 – 22-34
Paul et al. (357) 1945 Icteric Oral 5 4 – 22-34
Nasopharyngeal 
wash
Mac Cullum and  
Bradley (280)
1944 Icteric Nasopharynx 16 – 2 24-28
Neefe (334) 1945
Multiple  
stages
Nasopharynx 8 – – –
Havens (181) 1946 Icteric Nasopharynx 3 – – –
Urine
Voegt (467) 1942 Preicteric Oral 1 – (?) –
Mac Cullum and  
Bradley (280)
1944 Icteric
Nasopharynx 
and oral
19 – – –
Findlay and Wilcox (123) 1945 Icteric Oral 26 5 2 17-22
Neefe and Stokes (332) 1945
Multiple  
stages
Oral 7 – – –
Havens (181) 1946 Icteric Oral 3 – – –
Table 1 – Experiments on transmission of infectious hepatitis to volunteers
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Table 2 – Experiments on transmission of serum hepatitis to volunteers
Material Author Year Disease stage
Route of 
administration
Nr. of 
volunteers
Positive results
Incubation
(days)
Jaundice
Without 
jaundice
Feces
Neefe (335) 1945
Preicteric to 
icteric
Oral and 
intragastric
19 – – –
Mac Callum (281) 1945 Icteric Oral 15 – – –
Havens (186) 1946 Icteric Oral 6 – – –
Findlay et al. (122) 1944 Icteric Oral 2 – – –
Serum
Oliphant et al. (346) 1943 Icteric Parenteral 196 37 – 28-160
Oliphant et al. (346) 1943 Icteric Intranasal 3 – – –
Oliphant et al. (346) 1943
Convalescence 
(+75 days)
Parenteral 15 – – –
Mac Cullum and  
Bauer (282)
1944 Icteric Parenteral 16 6 – 50-127
Mac Cullum and  
Bauer (282)
1944 Icteric Intranasal 10 1 – 80
Mac Cullum and  
Bauer (282)
1944
66 to 141 
posticteric
Parenteral 10 – – –
Havens (186) 1944-46
Incubation  
(-16 days)
Parenteral 4 1 – –
Havens (181, 186) 1944-46 Icteric Parenteral 13 7 – 56-71
Havens (186) 1944-46
Convalescence 
(+28 to  
32 days)
Parenteral 5 – – –
Havens (181, 186) 1944-46 Icteric
Oral and 
intranasal
13 – – –
Neefe et al. (334) 1946 Icteric Parenteral 25 14 4 60-135
Neefe et al. (334) 1946 Icteric Oral 10 – – –
Neefe et al. (336) 1944
Incubation  
(-87 days)
Parenteral 2 2 – –
Paul et al. (357) 1945
Incubation
(-60 days)
Parenteral 8 3 – 94-132
Nasopharyngeal 
wash
Findlay and Martin (124) 1943 Icteric Intranasal 4 3 – 28-50
Mac Cullum (281) 1945 Icteric Intranasal 17 2 – 100
Neefe at al. (334) 1946 Icteric
Intranasal  
and oral
4 – – –
Urine Neefe et al. (334) 1946 Icteric Oral 1 – – –
A growing tendency to see epidemiological studies as a 
hierarchy of methods, conferring greater scientific value to 
experimental randomized studies and less value to obser-
vational studies must also be subject to discussion. 
Informing volunteers on possible hazards and dam-
ages to health as a result from experiments is a delicate 
task since there is always a margin of uncertainty for the 
researcher himself. To act ethically we must consider 
the principle of precaution for it is not always possible to 
evaluate risks as precisely as we would like to.
This principle in relation to prevention of hepatitis has 
been recently discussed by Harvey J. Alter33, co-discoverer 
of the Australia antigen and receiver of the Lasker Award 
for the study that led to the discovery of HCV and the 
development of screening tests that reduced transfusion 
hepatitis to almost zero34. Koch and Evans postulates are 
insufficient for today’s standards. The non-reproduction of 
hepatitis in vitro was overcome by electron microscopes and 
molecular biology that made possible the identification of 
HAV and HCV. The lack of application of the principle 
of precaution, or protection as referred by Schramm et al.8, 
may be contributing to the transfusional transmission of 
hepatitis in scientific research and in biomedical procedu-
res, due to the lack of substitution of old methods by newer 
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and safer technology, as determined by CNS Resolution 
196/967: “the principal investigator must stop the proto-
col immediately when any risk or damage to the health of 
the research subjects, not exposed in the informed con-
sent and consequent to research procedures, is detected” 
and “as soon as the advantage of a procedure over another 
is detected, the protocol must be suspended and the best 
procedure must be offered to all research subjects”. 
Keeping pace with scientific changes the legislation on 
the ethics of research must be reviewed to consider the 
uncertainty implied on the information given to volun-
teers and the possibilities of hazard30,35. Moreover, it is not 
enough that the legislation be regularly reviewed, but the 
investigator must exercise his responsibility by being ahead 
of the legislation when the preservation of the health and 
well being of the research subjects may be at issue.    
RESISTANCE TO REFORMULATION OF SCIENTIFIC CONCEPTS
The history of adverse effects of yellow fever vaccination of 
American soldiers in World War II offers a unique oppor-
tunity to discuss how the resistance to reconsider concepts 
and to change processes of production of pharmaceuti-
cal products may cause irreversible damage to health and 
retard the implementation of precautionary measures of 
control36,1,33.   
Since the 1930s, Findlay et al.4 had shown evidence of 
association between yellow fever vaccination and hepatitis 
and proposed that the vaccine be produced without the 
use of human serum. But it was only during World War 
II - when there were 28,585 cases of jaundice in American 
and other troops, with 62 deaths; and the American gov-
ernment and the scientific community became the targets 
of a hot press debate – that changes in the process of vac-
cine production were introduced36.
Other examples of this scientific resistance are the 
long intervals between the recognition of transfusional 
transmission of HBV and HCV and the implementation 
of preventive measures: 30 and 15 years respectively. Ac-
cording to Alter33: “This statement is being made not to 
cast retrospective blame, but to take a lesson from history 
and to illustrate the value of having a protective preemp-
tive mechanism in place before the next agent strikes.”
CONCLUSIONS
This brief historical view of the informed consent, focused 
on the case of hepatitis, points to its unequivocal role in 
the assurance of the autonomy of research subjects. But, it 
also leads us to ask if it is sufficient to preserve these sub-
jects from hazards. The answer seems to be no.  
We have shown factors that can interfere with free and 
informed consent of research volunteers. The complexity 
involved in the acceptance or refusal to be the subject of 
research must be considered by Ethics Committees and 
adequate means must be developed to further advance 
the protection of research subjects. An important compo-
nent for the preservation of the social value of scientific 
research is strict adherence to the legislation that aims to 
protect society.
Informed consent aims to protect and preserve the 
health of the research subjects and cannot be reduced 
to an instrument for the preservation of the integrity of 
research protocols. The responsibility of the researcher 
and the institution cannot be restricted to these proto-
cols, to preserve the credibility of both. The researcher 
also needs to be informed and to feel free to interrupt 
the research when he suspects that it may be causing 
harm to the subjects.
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